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Abstract
Background: To study late-life depression and its unfavourable course and co morbidities in The Netherlands.
Methods: We designed the Netherlands Study of Depression in Older Persons (NESDO), a multi-site naturalistic
prospective cohort study which makes it possible to examine the determinants, the course and the consequences
of depressive disorders in older persons over a period of six years, and to compare these with those of depression
earlier in adulthood.
Results: From 2007 until 2010, the NESDO consortium has recruited 510 depressed and non depressed older
persons (≥ 60 years) at 5 locations throughout the Netherlands. Depressed persons were recruited from both
mental health care institutes and general practices in order to include persons with late-life depression in various
developmental and severity stages. Non-depressed persons were recruited from general practices. The baseline
assessment included written questionnaires, interviews, a medical examination, cognitive tests and collection of
blood and saliva samples. Information was gathered about mental health outcomes and demographic,
psychosocial, biological, cognitive and genetic determinants. The baseline NESDO sample consists of 378 depressed
(according to DSM-IV criteria) and 132 non-depressed persons aged 60 through 93 years. 95% had a major
depression and 26.5% had dysthymia. Mean age of onset of the depressive disorder was around 49 year. For 33.1%
of the depressed persons it was their first episode. 41.0% of the depressed persons had a co morbid anxiety
disorder. Follow up assessments are currently going on with 6 monthly written questionnaires and face-to-face
interviews after 2 and 6 years.
Conclusions: The NESDO sample offers the opportunity to study the neurobiological, psychosocial and physical
determinants of depression and its long-term course in older persons. Since largely similar measures were used as
in the Netherlands Study of Depression and Anxiety (NESDA; age range 18-65 years), data can be pooled thus
creating a large longitudinal database of clinically depressed persons with adequate power and a large set of
neurobiological, psychosocial and physical variables from both younger and older depressed persons.
Background
The prevalence of major depression in older persons liv-
ing in the community ranges from 1-5%. [1] Rates of
depressive disorders are substantially higher among spe-
cific populations of older persons, ranging from 5-10%
in medical outpatients to 14-42% in residents of long-
term care facilities. [1] The prognosis of late-life
depression is often poor. [2] It appears to have a chronic
course and higher relapse rates compared to early-life
depression [3-6] and co morbidity with cognitive decline
and somatic diseases is higher than in depression in
younger adults. [7-9] In addition, in late-life depression
co morbidity with other psychiatric disorders, especially
anxiety disorders is high, [10-13] and leads to longer
time to remission as well as higher recurrence rates [14].
These findings suggest that the risk factors for late-life
depression and its course may change during lifetime.
According to the Stress-Vulnerability Model [15], the
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opment of depression and its course over time: vulner-
ability, stress and protective factors. However,
vulnerability factors, stressors and protective factors may
change over time, and the extent to which these factors
interact and influence mental health may change as
well. Former studies suggest that personality, genetic
factors as well as problems at work and in family rela-
tionships may play a larger role in the onset of depres-
sion at early age, whereas late-life depression has been
hypothesized to be more strongly associated with frailty-
associated processes and neurodegenerative biological
abnormalities. [16,17] It is shown that psychosocial as
w e l la sb i o l o g i c a lf a c t o r sp l a yar o l ei n( t h ec o u r s eo f )
late-life depression and its co morbidities. [4,18-23] Sev-
eral of these determinants are supposed to be common
in older adults, such as loneliness and losses in social
environment, [24] systemic low-grade inflammation [25]
and functional and cognitive limitations. [26] In addi-
tion, some of these determinants seem to function dif-
ferently in older compared to younger adults, such as
the hypo activation instead of hyper activation of biolo-
gical stress-regulation systems; the hypothalamic-pitui-
tary-adrenal (HPA)-axis and the autonomic nervous
system (ANS) [27-32].
Many of these determinants for late-life depression are
also interrelated, for instance, dysregulation of stress
regulating systems in turn give rise to dysregulation of
the immune system and to altered vascular and meta-
bolic processes, which may ultimately have deleterious
effects on the cardiovascular system, cognition and
mood regulation, [33,34] although studies in this field
show conflicting results. [35] More importantly, not
only can somatic diseases be a contributing or etiologi-
cal factor to late-life depression, late-life depression itself
also increases the risk of the development of new
somatic disease, such as cardiovascular disease
[23,36-40] and diabetes mellitus [41] and of physical
impairment [42].
A pronounced role for biological and neurodegenera-
tive underlying mechanisms in (the course of) late-life
depression may also explain the differences that have
been found between the symptom profiles of early- and
late-life depression. Compared to younger depressed
adults, older depressed persons were found to show
more psychomotor dysregulation and somatic distur-
bances such as fatigue and sleep disturbance [43,44] and
to have more apathy without the more traditional symp-
toms of depression [45,46].
To better understand late-life depression, and its
unfavourable course and co morbidities, we need long-
itudinal studies that integrate underlying psychosocial
and biological vulnerability and protective mechanisms.
Furthermore, it is still questioned in what way late-life
depression differs from depression earlier in life. Leav-
ing us with the question whether the concept of late-
life depression is similar to that of early-life depression
and, thus, to what extent we need differential diagnos-
tic criteria and treatment strategies. To be able to
make a direct comparison between early- and late-life
depression we need studies that have sufficient num-
bers of depressed persons in all age ranges. Therefore,
we designed the Netherlands Study of Depression in
Older Persons (NESDO; http://nesdo.amstad.nl) in
which the course of late-life depression and its co
morbidities will be followed up in detail in a prospec-
t i v ed e s i g n .T ob ea b l et om a k ead i r e c tc o m p a r i s o n
between early- and late-life depression, NESDO uses
the same design and overlapping instruments as the
Netherlands Study of Depression and Anxiety
(NESDA). [47] NESDA has collected data from a large
cohort of persons with depressive and anxiety disor-
ders aged 18 through 65 years (N = 2,981), which
makes it possible to directly compare data from the
older cohort with the existing data from depressed
younger persons from NESDA (n = 1,149), thus creat-
ing a large longitudinal database of clinically depressed
persons with adequate power and a large set of neuro-
biological, psychosocial and physical variables from
both younger and older depressed persons.
Aims of the study
T h ef i r s ta i mf o rN E S D Oi st oe x a m i n et h ed e t e r m i -
nants of late-life depression. The second aim is to exam-
ine the course, the determinants of the course and the
consequences of depressive disorders in older persons.
The third aim is to compare the determinants of late-
life depression, and the course and its determinants with
that of early-life depression.
Methods
Sample
Recruitment of depressed older persons took place in
five regions in the Netherlands from both mental health
care institutes and general practitioners in order to
include persons with late-life depression in various
developmental and severity stages. Persons with a pri-
mary diagnosis of dementia, were suspected for demen-
tia according to the clinician or had a Mini Mental
State Examination-score (MMSE) under 18 (out of 30
points) were excluded. Also persons with insufficient
command of the Dutch language were excluded. Non-
depressed controls were included in order to answer
research questions on the aetiology of depression, and
were recruited from general practitioners. Inclusion cri-
teria for non-depressed controls were: no lifetime diag-
nosis of depression or dementia, and good command of
the Dutch language. Data collection of the first
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tember 2010.
Three hundred and twenty-six persons of the
depressed older persons (86.2% of the depressed sample)
were recruited from the out- and inpatient clinics of the
regional facilities for mental health care: Amsterdam (n
= 113), Leiden (n=70), Apeldoorn/Zutphen (n=50),
Nijmegen (n=47) and Groningen (n=46). Patients
with a primary diagnosis of major depression, dysthymia
or minor depression according to DSM-IV criteria [48]
and who were mentally able to give written informed
consent received verbal and written information about
NESDO and were asked to participate. Response rates
a r eo n l ya v a i l a b l ef r o mA m s t e r d a m ,b u tt h e s em a yb e
considered representative for the other mental health
institutions. In the region of Amsterdam, 294 persons
with a depressive disorder were enrolled to the study.
Of these, 291 (99%) were contacted by telephone and 3
(1.0%) could not be reached despite multiple efforts. Of
the persons who were approached by telephone, 57 per-
sons (19%) were excluded because of meeting the exclu-
sion criteria: 23 (7.8%) had had no depressive symptoms
in the past 3 months, 14 (4.7%) were not able to
undergo the interview because of severe mental illness
or severe physical or cognitive frailty, and 6 (2.0%) were
excluded because of language problems during the
phone contact. Of the remaining 234 persons who ful-
filled the inclusion criteria, 121 persons (51.3%) refused
and 113 (48.7%) were willing to participate in NESDO.
Compared with those who refused to participate, per-
sons who participated in the baseline interview were
comparable in gender, but were younger (72.0 years ver-
sus 74.2 years, p < 0.03).
The primary care patients (n=52) and the non-
depressed control group (n=132) were recruited from
14 general practices (GPs) in the vicinity of Amsterdam,
Groningen and Leiden. Depressed persons were referred
by the GPs because of depressive complaints (n=17),
or after screening with the fifteen item version of the
Geriatric Depression Scale (GDS-15; n=35). [49] A
screen positive score on the GDS-15 was defined as a
score of 4 or higher. In total, 242 screen positive per-
sons were contacted for a short phone-screen interview
of whom 58 (24.0%) fulfilled the criteria for a current
depression and the exclusion criteria. Of these, 23
(39.7%) refused to participate in the NESDO study, and
35 persons (60.3%) with a current depressive disorder
underwent the baseline assessment. In addition, a ran-
dom selection of screen-negative persons (n=198) were
approached for a short phone-screen and those who ful-
filled the criteria for a non-depressed control and had
sufficient command of the Dutch language were invited
to participate in NESDO. Of these, 132 (66.7%) were
willing to participate in the study.
Sample size
Our sample size calculations indicated that for cross-
sectional analyses with the baseline NESDO sample and
a power of 80% and an alpha of 0.05 we will be able to
detect small differences with respect to clinical variables
and questionnaires. For the biological determinants we
need to extend the sample with persons of 60-65 years
from NESDA (depressed persons: N=77; normal con-
trols N=102), which results in a sample of 455
depressed and 234 non-depressed elderly, to detect
moderate effects in the biological measures. When we
extend the NESDO sample with younger age groups, the
sample size will be suitable to detect even small effects
in these biological measures.
For the analysis on the course of depression, we need
a minimum of 255 persons to detect an odds ratio of
1.4 in a multiple logistic regression models with a cate-
gorical outcome variable (for instance, presence of
depression diagnosis yes/no) with a power of 80% and a
l e v e lo fs i g n i f i c a n c eo f0 . 0 5 .I nam u l t i p l er e g r e s s i o n
models with a continuous change variable as outcome
(for example change in severity of depressive symp-
toms), with a sample size of 255 and a power of 80%
and an alpha of 0.05, we are able to detect a 5% change
in the variance. So, the sample size is adequate to
demonstrate statistical significances for even small dif-
ferences. If we would examine change in the outcomes
combining the 3 follow-up assessments using a multi-
level analyses, our power would even be substantially
higher than in the above described examples.
Assessment
The Stress-Vulnerability Model [15] that suggests that
the interaction of vulnerability, stress and protective fac-
tors are responsible for the development of depression
and its course over time has guided the selection of the
instruments. The baseline assessment included interna-
tionally accepted, commonly used measures for demo-
graphic variables, depression, psychosocial variables,
(chronic) stressors, activity of the HPA-axis, (re)activity
of the ANS, parameters for inflammation, somatic co
morbidity, cognitive functioning and the use medication
and health care services (Table 1). The baseline assess-
ment took place in the morning and lasted 3 to 4
hours. It included written questionnaires, an interview,
a medical examination, assessment of the ANS (re)activ-
ity, collection of blood and instructions for sampling of
the saliva. The baseline assessment was mainly per-
formed at the different participating sites. When partici-
pants were not able to come to the site, they were
interviewed at their homes. Furthermore, when neces-
sary, the assessment was spread over two appointments.
After the assessment, the participants were compensated
with a small incentive (gift certificate of 15 euro and
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Participants are given feedback about the research pro-
gram by means of yearly newsletters. Furthermore,
there was prompt response to any question or letter
from the participants. Cooperation was facilitated by
offering the participants a mix of self-report question-
naires, interviews, biological measures and cognitive
tests.
Assessment of psychopathology
Diagnosis of depression and dysthymia according to
DSM-IV-R criteria [48] is assessed with the Composite
International Diagnostic Interview (CIDI; WHO version
2.1; life-time version). The CIDI is a structured clinical
interview that is designed for use in research settings
and has high validity for depressive and anxiety disor-
ders. [9,50] As in NESDA, we added questions to
Table 1 Baseline assessment of NESDO
Topic Measurement instrument
Demographics: Age, gender, education, SES
a,
religion, partner status, family
Standard questions
Diagnostics Composite Interview Diagnostic Instrument (CIDI) -version 2.1 World Health Organization
(WHO), 1997: depressive and anxiety disorders
Psychopathology
- Depression, severity Inventory of Depressive Symptoms (IDS; Rush et al., 1996,
- Apathy, severity Apathy Scale (Starkstein et al., 1992)
- Anxiety symptoms Beck Anxiety Index (Beck et al., 1988)
Physical conditions
- Chronic diseases LASA
a Questionnaire (Kriegsman et al., 1996)
- Pain Chronic Graded Pain Scale (Von Korff & Miglioretti, 2005)
- Vision and hearing LASA
a Questionnaires http://www.lasa-vu.nl/index.htm
- Sleep Insomnia Rating Scale (Levine et al., 2003)
- Functional limitations WHO-Disability Assessment Scale (Chwastiak et al., 2003)
- Medication use Registration of medication use
- Smoking & drugs Past & current smoking questions
- Alcohol dependency Alcohol Use Disorders Identification Test (Babor et al., 1989)
- Physical Activities International Physical Activities (Craig et al., 2003)
Biological determinants
- Inflammation markers, BDNF
a & polymorphism Fasting blood sample
- Autonomic Nervous System Electrocardiography & impedance cardiography (VU-AMS; de Geus et al., 1995)
- Cortisol 6 saliva samples, including Dexamethasone Suppression Test (Wüst et al., 2000; APA 1986)
Psychol. determinants
- Personality: Big Five NEO-Five Factor Inventory (Costa & McCrae, 1995)
- Mastery Pearlin Mastery scale (Pearlin & Schooler 1978)
- Daily Hassles Worry Scale-R (Wisocki, 1986)
Social determinants
- Early life events NEMESIS questionnaire (De Graaf et al., 2004)
- Recent life events Brugha Questionnaire (Brugha et al., 1985)
- Loneliness and affiliation Loneliness and affiliation scale (De Jong Gierveld & Kamphuis, 1995)
- Social support Close Person Inventory (CPI; Stansfeld et al., 1992)
Cognitive functioning
- Global cognitive functioning Mini-Mental State Examination (Folstein et al. 1975)
- Executive functioning Stroop Color-Word test (short form) (Stroop 1935)
- Motivational problems Digit Span (subtest WAIS
a) (Wechsler, 1958)
- Memory function Auditory Verbal Learning Test (Rey, 1964; van der Elst et al. 2005)
Use of Care Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (Hakkaart-van Roijen,
2002)
a SES Social Economic Status; LASA Longitudinal Aging Study Amsterdam; BDNF brain-derived neurotrophic factor; WAIS Wechsler Adult Intelligence Scale
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minor depression. Severity of depression was measured
using a self-report questionnaire: the Inventory of
Depressive Symptoms (IDS). [51] As co morbidity with
anxiety disorders is high, anxiety disorders [General
Anxiety Disorder (GAD), Panic Disorder (PAN), Agora-
phobia (AGO) and Social Phobia (SOC)] were also
assessed using the CIDI (12 month version). Severity of
anxiety symptoms was measured using the Beck Anxiety
Index (BAI), [52] a self-report questionnaire. Apathy
w h i c hi sa s s u m e dt ob em o r ec o m m o ni nl a t e - l i f e
depression compared to early-life depression was
assessed using the Apathy Scale as a self-report ques-
tionnaire [53].
Vulnerability factors, stressors and protective factors
Demographic characteristics such as age, sex, ethnicity,
place of living, household composition, and income
were assessed with standard questions.
Psycho-social functioning
Childhood abuse, including emotional neglect as well as
psychological, physical and sexual abuse, was assessed
using a structured inventory. [54] Important life events
during childhood and in the past years were assessed
w i t ht h eB r u g h aq u e s t i o n n a i r e .[ 5 5 ]P e r s o n a l i t yw a s
assessed with the NEO-FFI, a 60 item questionnaire
measuring the five personality domains neuroticism,
extraversion, agreeableness, conscientiousness, and
openness to experience [56] and a short mastery scale.
[57] Daily hassles were assessed using a revised version
of the Worry-Scale. [58] Details about present social
support from the four most intimate persons were
assessed with the Close Person Inventory, [59] and a
self-report questionnaire on loneliness and affiliation
[60].
Somatic and health markers
The presence of chronic diseases was assessed by means
of a self-report questionnaire that has previously been
used in NESDA. [47] The participants were asked
whether they currently or previously had any of the fol-
lowing chronic diseases or disease events: cardiac dis-
ease (including myocardial infarction), peripheral
atherosclerosis, stroke, diabetes mellitus, COPD (asthma,
chronic bronchitis or pulmonary emphysema), arthritis
(rheumatoid arthritis or osteoarthritis) or cancer, or any
other disease. Compared to general practitioner infor-
mation, the accuracy of self-reports of these diseases
was shown to be adequate and independent of cognitive
impairment [61].
Biomarkers that are parameters of cardiovascular sta-
tus, immune function and metabolic syndrome were
assessed in fasting blood. The interviews took place in
the morning, and the respondents came in after an over-
night fast. We drew 47.5 millilitres of blood which was
immediately transferred to a local laboratory to start
processing within an hour. Routine assays included
assessment of haemoglobin, hematocrit, creatinine, total
cholesterol, HDL and LDL cholesterol, glucose, trigly-
cerides, albumin, thyroid stimulated hormone (TSH)
and Free T4. The rest of the blood was processed and
stored at −80°C for later assaying.
Systolic and diastolic blood pressures were measured
twice in a supine position using an electronic Omron
phygmomanometer. Doppler assessment of ankle and
arm blood pressure allows calculation of the ankle/bra-
chial index, which is an indicator of peripheral athero-
sclerosis [62].
Physical condition was assessed by means of measure-
ment of handgrip using a hand-held dynamometer,
which is an important indicator of physical frailty. Body
composition assessment included objective, standardized
assessments of height, weight and hip and abdominal
circumference. Self reported functional limitations were
assessed with the WHO-Disability Assessment Schedule.
[63] Pain was assessed with the self report Chronic
Graded Pain scale. [64] Sleep and insomnia was assessed
with the Insomnia Rating Scale (IRS). [65] Vision and
hearing were assessed with standard questions.
Physical stress regulation systems
The two most important biological stress regulation
systems that have been hypothesized to be of impor-
t a n c ei nd e p r e s s i o na r et h eH P A - a x i sa n dt h ea u t o -
nomic nervous system (ANS). Functioning of the
HPA-axis was assessed by the use of cortisol concen-
trations in saliva, reflecting the free fraction of plasma
cortisol, which was collected by the participants on
two consecutive days. [66] Six saliva samples were
taken: at the time of awakening (T1), 30 minutes post-
awakening (T2), 45 minutes post-awakening (T3), 60
minutes post-awakening (T4) and at 22:00 h (T5).
Dexamethasone suppression was measured by sampling
the next morning at awakening (T6) after dexametha-
sone ingestion of 0.5 mg the night before (directly
after T5). This Dexamethasone Suppression Test
(DST) is a measure of HPA axis regulation and nor-
mally shows a decrease of morning cortisol concentra-
tions due to inhibition of adrenocorticotropic hormone
(ACTH) secretion after dexamethasone administration
the night before. [67] The salivettes were restored in
the tube labelled with date and time. After collecting
all six samples, the subjects were asked to return the
samples by post to the research centre. After receipt,
salivettes were centrifuged at 2000 g for ten minutes,
aliquoted and stored at −20°C.
The assessment of ANS functioning included heart
rate, pre-ejection period and respiratory sinus arrhyth-
mia, and was measured with the ambulatory recording
system developed at the VU University in Amsterdam
Comijs et al. BMC Research Notes 2011, 4:524
http://www.biomedcentral.com/1756-0500/4/524
Page 5 of 10(VU-AMS, version 5 fs). Recording methodology of the
VU-AMS as well as its reliability, validity and feasibility
in large scale samples has been well documented
[68,69].
Cognitive function
Tests for several cognitive domains were assessed: the
Mini-Mental State Examination (MMSE) [70] for global
cognitive functioning, the abbreviated version of the
Stroop Colour-word test [71] for executive functioning;
the subtest Digit Span from the Wechsler Adult Intelli-
gence Scale [72] for motivational problems and a modi-
fied version of the Auditory Verbal Learning Test
[73,74] for memory function.
Health behaviour
Assessment of health behaviour included smoking, alco-
hol use, physical activities and use of health care and
medication. Smoking behaviour was assessed with stan-
dard questions, and the use of alcohol was assessed using
the Alcohol Use Disorders Identification Test (AUDIT).
[75] With the International Physical Activities Question-
naire (IPAQ) [76] energy expenditure based on sports
and daily activities was calculated. Medical and psycholo-
gical treatments and other professional support the per-
sons have had for their mental and physical health
problems was assessed with the Trimbos/iMTA ques-
tionnaire for Costs associated with Psychiatric Illness
(TIC-P). [77] Medication use was determined by observa-
tion of the medication that the participants brought in.
Longitudinal data collection
The course of late-life depression is followed up every 6
months by means of a postal assessment that includes
questionnaires on the severity of depressive symptoms
and somatic health in the past 6 months, incident
(chronic) stressors and functional limitations, and use of
medications and health care. The questionnaires are the
same questionnaires that are used during the face-to-
face assessments.
A second face-to-face assessment is being performed 2
years after the baseline assessment, and is currently
going on. It consists of all measures (determinants and
outcome variables) that are open to change, such as
severity of psychopathology and diagnostics, change in
socio-demographic characteristics, all somatic health
and health markers, cognitive functioning, psycho-social
functioning (except for the early life events and the per-
sonality questionnaire), and health behaviour. More
detailed fluctuation of depressive symptoms during the
past 2 years will be assessed with a Life Chart method.
This instrument uses a calendar method to re-fresh
memory and then assesses presence and severity of
symptoms during each month in the past two years.
[78] Collection of blood and VU-AMS registration are
also repeated.
The follow-up assessment lasts about 3 hours and the
same instruments will be used as in the baseline assess-
ment (see Table 1), including written questionnaires, an
interview, and a medical examination. A third follow-up
face-to-face assessment is planned 6 years after the
baseline assessment.
Quality of the data
All interviews and physical examinations are conducted
by carefully selected research assistants, mainly consist-
ing of psychologists and mental health care nurses. The
research assistants received a five day training from an
experienced and certified trainer before the baseline and
follow-up assessments. The research assistant is certified
to conduct assessments after approval of two complete
interviews which were audio taped and judged by the
trainer. Question wording and probing behaviour of
interviewers will frequently be monitored by checking a
random selection of about 10% of all taped interviews.
Data are collected with Computer Assisted Personal
Interviewing (CAPI) procedures on laptop computers
and with self-administered questionnaires.
Data management and control
Data management of NESDO is coordinated at the
Department of Psychiatry of the VUMC. The collected
data from the different sites are send to the coordinating
centre, where the data are entered in the central data-
base. A special team of data managers takes care of data
quality, data archiving and the creation of variables and
scales. Data quality check procedures are in place and
are routinely carried out to review missing data and
check for inconsistencies.
Ethical issues
The study protocol of NESDO has been approved cen-
trally by the Ethical Review Board of the VU University
Medical Center, and subsequently by the local ethical
review boards of the Leiden University Medical Center,
University Medical Center Groningen and the Radboud
University Medical Center in Nijmegen. Before partici-
pating in the study, all persons were provided with oral
and written information. Written informed consent was
obtained from all participants at the start of the baseline
assessment. Written informed consent was asked for
participating in the study, for permission to use genetic
information, to retrieve medical information from the
GP’s, and to link information to external databases. A
privacy protocol has been developed in which confiden-
tiality of data is guaranteed by using a unique research
ID number for each respondent, which enables to iden-
tify individuals without using their names. Only the data
manager has access to the record that links the ID num-
ber with the name of the participant.
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T h eb a s e l i n es a m p l ec o n s i s t s of 378 depressed persons
and 132 non-depressed controls. The overall sample has
a mean age of 70.6 years (SD: 7.3; range = 60-93) and
consists of 331 (64.9%) women and 179 (35.1%) men.
The average years of education is 11.0 (SD = 3.6; range
5 - 1 8y e a r s ) .T h em a j o r i t yo ft h es a m p l eh a st h eD u t c h
nationality (99.4%).
The depressive persons do not differ from the non-
depressed controls with respect to mean age and sex,
but they have a lower level of education, are more often
divorced or widowed, and have a lower score on the
MMSE (Table 2). From the depressed persons 95% has
a current (six-month) major depressive disorder, 26.5%
has dysthymia and 5.6% has a minor depression. 26.5%
of the depressed persons have two depressive disorders,
m a j o rd e p r e s s i v ed i s o r d e ra n dd y s t h y m i a( T a b l e3 ) .
Mean age of onset of the depressive disorders was
around 49 years. About thirty percent of the persons
with major depression (MDD) and dysthymia had an
onset before the age of 40 years, whereas about 33% of
the persons with MDD and 41% of the persons with
dysthymia had an onset after 60 years. For 33.1% of the
depressed persons it was their first episode. Severity of
the depression symptoms varied between mild and very
severe. Forty-one percent of the depressed persons had
in the past 6 months also an anxiety disorder.
Discussion
NESDO is a multi-site naturalistic cohort study that
offers us the possibility to examine the determinants, the
course and consequences of depressive disorders in older
persons, and to compare these with those of depression
earlier in adulthood. Because of the increase of the aging
population in the near future, the number of older per-
sons suffering from (chronic) depression will further
grow in the forthcoming years, and thus will become an
even more relevant issue for public health care. It is of
great importance to uncover mechanisms responsible for
its chronic course and co morbidity. Differences in (the
determinants of) the course and consequences of depres-
sion have seldom been directly compared between older
and younger adults using a similar study design and with
comparable instruments. Knowledge about the adequacy
of the postulated differences between late-life and early-
life depression is important, since it will yield important
implications for mental health care practice and research.
By combining data from NESDA and NESDO we will be
able to address important questions that have potential
relevance to the development of interventions capable of
improving the course of late-life depression. The clinical
relevance of the study is enhanced by the fact that several
determinants of the course of depression may be used in
prevention and treatment programs, which may be
implemented in regular care.
Conclusions
The NESDO sample offers the opportunity to study the
(determinants) of the long-term course of depression in
older persons, and to pool data with NESDA. This pro-
vides us with a large (longitudinal) database of clinically
depressed persons with adequate power and a large set
of neurobiological, psychosocial and physical variables
from both younger and older depressed persons.
Table 2 Characteristics of the sample (N=510)
Depressed persons (n=378) Non-depressed controls (n=132) p
Age, mean (SD) 70.7 (7.4) 70.1 (7.2) 0.37
- 60-69, n (%) 189 (50.0) 74 (56.1) 0.48
- 70-79, n (%) 132 (34.9) 40 (30.3)
- > 80, n (%) 57 (15.1) 18 (13.6)
Female, n (%) 250 (66.1) 81 (61.4) 0.34
Level of education < 0.001
- Low, n (%) 78 (20.6) 9 (6.8)
- Middle, n (%) 221 (58.5) 71 (53.8)
- High, n (%) 79 (20.9) 52 (39.4)
Marital status 0.001
- Never been married, n (%) 30 (7.9) 10 (7.6)
- Married, n (%) 174 (46.0) 86 (65.2)
- Living apart, n (%) 16 (4.2) 0
- Divorced, n (%) 54 (14.3) 10 (7.6)
- Widow(er), n (%) 104 (27.5) 26 (19.7)
Cognitive function, mean MMSE
1 (SD) 27.69 28.34 0.001
1 MMSE: Mini-Mental State Examination
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